Equities analysts expect argenx SE – (NASDAQ:ARGX) to announce earnings of ($1.29) per share for the current quarter, according to Zacks. Five analysts have made estimates for argenx’s earnings, with the highest EPS estimate coming in at ($1.13) and the lowest estimate coming in at ($1.60). The business is scheduled to report its next quarterly earnings report on Thursday, August 1st.
On average, analysts expect that argenx will report full year earnings of ($4.01) per share for the current financial year, with EPS estimates ranging from ($4.45) to ($3.39). For the next fiscal year, analysts expect that the firm will post earnings of ($6.64) per share, with EPS estimates ranging from ($9.52) to ($5.00). Zacks’ earnings per share averages are an average based on a survey of analysts that that provide coverage for argenx.
A number of analysts have recently commented on ARGX shares. Robert W. Baird started coverage on shares of argenx in a research note on Thursday, June 27th. They issued an “outperform” rating and a $170.00 price target for the company. Cowen started coverage on shares of argenx in a report on Friday, September 13th. They issued a “buy” rating on the stock. Morgan Stanley raised their price objective on shares of argenx from $143.00 to $173.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Stifel Nicolaus reissued a “buy” rating and issued a $154.00 price objective on shares of argenx in a report on Thursday, August 1st. Finally, ValuEngine downgraded shares of argenx from a “hold” rating to a “sell” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $155.10.
Shares of ARGX stock traded up $0.79 during trading hours on Monday, reaching $112.67. The company had a trading volume of 141,116 shares, compared to its average volume of 167,538. The business has a fifty day moving average price of $127.30 and a 200-day moving average price of $130.58. argenx has a one year low of $63.81 and a one year high of $150.92. The firm has a market cap of $4.29 billion, a PE ratio of -47.94 and a beta of 1.20.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Recommended Story: How dollar cost averaging works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.